Compare Manchester United PLC (MANU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Medpace Holdings Inc — how do they compare? Manchester United PLC trades at $20.52 (market cap $3.51B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 4.8× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Medpace Holdings Inc for 14 Days on average.
| MANU | MEDP | |
|---|---|---|
Market Cap | $3.51B | $16.82B |
Volume | 412,769 | 223,093 |
Sector | Media | Health |
52-Week High | $24.19 | $630.19 |
52-Week Low | $15.20 | $393.42 |
Typical Hold Time | 109 Days | 14 Days |
Enterprise Value | $4.33B | $16.44B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.60, up 1.73% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but negative net income margins and ROE. Analyst sentiment is divided with 40% buy ratings, while cash flow trends show heavy investment spending offset by financing activities.
The stock presents a valuation disconnect opportunity with market cap below Forbes' franchise estimates, but faces execution risks from persistent losses and high debt load. Upside depends on Champions League revenue conversion and cost management, while downside risks include sustained profitability challenges in the competitive sports landscape.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
